FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff
The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna.
Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers.
But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are rare.
Instead Prasad decided the shots should be limited to those who face special risks from the virus— seniors or children and adults with underlying medical issues.
Prasad explained that the COVID vaccine benefits must be reconsidered in light of falling rates of death and hospitalization and the possibility for vaccine side effects. It's the latest in a series of vaccine restrictions imposed by officials working under Kennedy, who has long questioned the benefits of vaccines.
'Even rare vaccination related harms both known and unknown now have higher chance of outweighing potential benefits' Prasad wrote in a five-page memo explaining his decision.
COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months.
Top FDA leaders are typically not involved in the review of individual products. Officials like Prasad can overrule staffers, but such cases are rare and often controversial.
News of the FDA documents was first reported by the New York Times.
Prasad was hired to lead the FDA's vaccine center in May, after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy. An academic researcher specializing in cancer therapies, Prasad came to prominence during the pandemic for criticizing public health measures, including the FDA's approval of COVID boosters for healthy adults and children.
Since arriving at the agency he has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity.
Those limits match the terms FDA recently approved for Novavax's shot, Nuvaxovid and Moderna's mNexspike. Novavax's vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna's vaccine is an updated, lower-dose version of its existing mRNA-based vaccine.
The review team for the Novavax vaccine pointed to data from a study in 30,000 adults, concluding that 'the risk-benefit assessment for this vaccine technology remains favorable.'
FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company's original shot.
Last week, the FDA finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer, the other maker of an mRNA-based shot for COVID.
In his 'override memo,' reversing FDA staff's decision on the Moderna shot, Prasad pointed to the ongoing risk of myocarditis and questions about its frequency. The agency ordered Moderna to conduct further studies of the risk as a condition for the approving its updated shot.
A spokesman for the administration said Prasad 'has raised serious concerns' about the issue.
'We will not ignore these risks and will ensure that the gold standard of science is used for any decisions,' said Andrew Nixon, in an emailed statement.
Outside researchers have noted that cases of the heart condition tend to resolve quickly and are less severe than those associated with COVID infection itself, which can also cause myocarditis.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
How To Embrace Neurodiversity In The Workplace To Improve Innovation
How To Embrace Neurodiversity In The Workplace To Improve Innovation Neurodiversity means there is no single "correct" way for the brain to work. The reality is that the workplace includes people who have a wide range of conditions, including autism spectrum disorder, ADHD, dyslexia, and learning disabilities. Research has found that 19% of Americans identify as neurodivergent. Neurodiverse individuals can bring "fresh eyes" to problems. Their unique ways of thinking are valuable because employees often get stuck in doing things the way they have always done them. When you bring in someone who has a unique perspective or has not been influenced by status-quo thinking, that is when the best ideas can happen. When individuals stay focused, question routines, and bring original thinking that challenges assumptions, it creates innovative ideas. Sometimes these thinkers go unnoticed, or worse, ignored. But when leaders start paying attention to how people solve problems, that is when their teams adapt faster, think more clearly, and produce stronger results. How Can Neurodiversity In The Workplace Improve Problem-Solving? How Can Neurodiversity In The Workplace Improve Problem-Solving? When team members think differently, they often notice things that others miss. This is especially true when facing complex challenges that have no clear solution. A Deloitte study found that teams including neurodivergent talent outperformed others on tasks requiring creativity, accuracy, and pattern recognition. These thinkers tend to spot gaps in logic, inconsistencies in data, or errors in execution before anyone else does. Some companies have started to see how problem-solving improves when diverse minds are involved from the beginning. SAP's Autism at Work program led to measurable increases in productivity across several teams. They noticed that when neurodivergent employees were hired and supported properly, their ways of working led to better questions, deeper analysis, and clearer workflows. Fresh ideas often come from people who have not been conditioned to accept what everyone else accepts. Neurodivergent individuals often bring that perspective because they experience the world differently. What Makes Neurodiversity In The Workplace Difficult To Manage? What Makes Neurodiversity In The Workplace Difficult To Manage? Leaders often say they support inclusion, but they sometimes overlook what inclusion really involves. Neurodiversity introduces differences in communication, work rhythms, and ways of processing information. These differences can be misunderstood as performance issues when the real issue is a mismatch between the environment and the person's strengths. Many neurodivergent professionals report that unspoken rules are the hardest part of working in a traditional office. If someone needs more time to respond, prefers written instructions, or skips small talk, they may be misjudged as uncooperative or disengaged. But when managers get specific about goals and outcomes, they start to see that these same employees often produce more consistent, high-quality results than expected. The mistake is assuming one communication style or workflow suits everyone. That assumption limits potential and often leads to disengagement. When leaders ask questions instead of making assumptions, they open the door to understanding how to bring out the best in each person. What Should Leaders Do To Support Neurodiversity In The Workplace? What Should Leaders Do To Support Neurodiversity In The Workplace? Support starts with curiosity and the willingness to meet people where they are. A simple question like 'How can I help you do your best work?' can lead to a breakthrough. That question signals that differences are respected. Many of the adjustments that help neurodivergent employees—like using clear written communication, offering flexible deadlines, or minimizing background noise—benefit everyone. Instead of singling people out, this designs work in a way that supports how the brain functions under pressure. There are also cultural shifts that leaders can make. Try having meetings that include time for reflection, allow written follow-ups instead of immediate responses, and avoid fast-paced brainstorming where only the loudest voices are heard. These changes can increase inclusion without compromising results. How Does Neurodiversity In The Workplace Increase Innovation? How Does Neurodiversity In The Workplace Increase Innovation? Innovation grows in teams that welcome mental friction. Not the kind that creates conflict, but the kind that invites different patterns of thinking. Neurodivergent individuals are often the ones who explore ideas that seem unconventional. This kind of focus is especially valuable in roles that require deep concentration or attention to detail. For example, JPMorgan Chase launched a program to recruit autistic talent for quality assurance and cybersecurity roles. They reported higher productivity, lower error rates, and greater retention in those roles compared to traditional hires. These outcomes came from giving employees the freedom to approach their work in the way that suited them best. How Can You Build A Workplace That Embraces Neurodiversity Starting This Week? How Can You Build A Workplace That Embraces Neurodiversity Starting This Week? You can start building a workplace that embraces neurodiversity by using both written and verbal communication. After meetings or assignments, follow up with a quick written summary. It helps those who process information more slowly and makes instructions easier to refer back to. Ask about preferred work styles. Not everyone works best under pressure or in noisy environments. Some thrive on routines, while others need more autonomy. Listen when people tell you what works for them. Using vague terms like 'be more engaged' or 'speak up more' is not helpful. Be specific and focus on the quality of their contributions. Why Neurodiversity In The Workplace Deserves More Attention Now Why Neurodiversity In The Workplace Deserves More Attention Now As jobs become more complex, companies will need to create space for different types of minds to thrive. The goal is to recognize that these individuals often hold the key to better outcomes. Neurodiversity already exists in your organization. The question is whether these people's strengths are being seen, heard, and supported. When organizations build a culture that embraces curiosity, they begin asking better questions about support, performance, and leadership. In that process, they often discover that some of their most overlooked employees may also be their most innovative.
Business Upturn
4 hours ago
- Business Upturn
Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence
Alembic Pharmaceuticals Inc., the wholly owned US subsidiary of Alembic Pharmaceuticals Limited, has announced the acquisition of UK-based Utility Therapeutics Ltd. This strategic move marks Alembic's entry into the branded anti-infective segment in the United States, particularly focusing on treatments for urinary tract infections (UTIs). Utility Therapeutics is engaged in developing pharmaceutical products aimed at combating UTIs, a widespread medical condition in the US. The acquisition brings two key assets into Alembic's fold — 'Pivya,' an FDA-approved treatment for uncomplicated UTIs, and 'MEC,' a pipeline product currently under development to address complicated UTI cases. Alembic Pharmaceuticals sees this acquisition as a significant step towards strengthening its presence in the US market with branded specialty products. The deal allows Alembic to market Utility's assets in the US, leveraging the regulatory approvals already in place and continuing the development of promising pipeline therapies. The total consideration for the acquisition is expected to be around $12 million, paid in a staggered manner depending on the achievement of specific milestones. It also includes a provision for profit sharing based on future earnings generated by Utility's products. The transaction does not fall under the related party category, and none of the promoters or group companies have any financial interest in the deal. Completion of the acquisition is anticipated within approximately 30 days, and no additional regulatory approvals are required. This acquisition aligns with Alembic's strategy of expanding its global footprint and diversifying its product offerings in regulated markets like the US. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Associated Press
6 hours ago
- Associated Press
Global Kratom Coalition Applauds FDA Action Against Hydroxie and Expects Broader Crackdown Against Synthetic Opioids Like 7
FDA action aligns with a growing chorus of scientists, public health experts, and advocates warning against the public health risk associated with the proliferation of 7 The Global Kratom Coalition (GKC) today commended the U.S. Food and Drug Administration (FDA) for issuing a comprehensive and forceful warning letter to Hydroxie, LLC, a seller of synthetic 7-hydroxymitragynine (otherwise known as '7') products falsely marketed as dietary supplements, shots, and drink mixes. The GKC hailed the move as a critical step in addressing these products that masquerade as natural dietary supplements but are actually unapproved new drugs. 'This warning letter is a major step in a broader effort to remove dangerous '7' products from store shelves and online marketplaces,' said Walker Gallman, Legislative Director of the Global Kratom Coalition. 'These actions should protect consumers and safeguard the integrity of the dietary supplement marketplace. It should result in a cascade of warnings to other 7 makers.' In the June 25, 2025, letter , the FDA identified multiple violations of the Food, Drug, and Cosmetic Act, citing Hydroxie's products as both unapproved new drugs and adulterated food. The FDA noted that Hydroxie's 7 products—including its 'Hydroxie 15mg 7-OH Tablets,' 'Hydroxie Red Shots,' and 'Hydroxie 7-OH Drink Mix"—are marketed with drug claims and contain an ingredient not generally recognized as safe. 'Your Hydroxie 15mg 7-OH Tablets, Hydroxie Red 15mg Tablets... are drugs as defined by section 201(g)(1) of the FD&C Act... because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease,' the FDA stated in the letter. 'Based on our review... the use of 7-OH in conventional food does not satisfy the criteria for GRAS status... [and] raises serious concerns about potential harm associated with 7-OH,' the agency warned. 'This is a watershed moment,' said Gallman. 'The FDA has now publicly and definitively recognized that products like Hydroxie's, which are made up of synthetically boosted and highly concentrated levels of 7-hydroxymitragynine, are deceptively marketed as dietary supplements or conventional foods and are illegal. They are not kratom products; they are not dietary supplements; they are not legal; they are unapproved drugs and adulterated foods masquerading as legal, natural products.' FDA Warning Letter Addresses Persistent 'Bad Actors' Damaging Industry The GKC has long warned that certain actors in the marketplace are undermining public trust in the dietary supplement industry by selling synthetically enhanced or adulterated 7 products, often under the guise of 'all natural' or 'dietary supplement' or as 'kratom'. However, these products are marketed by the companies that sell them and the advocacy organizations that support them ( Holistic Alternate Recovery Trust (HART) and 7-Hope Alliance ) as drugs to treat chronic pain and opioid use disorder. The FDA's letter made clear that: 7 has not been evaluated by the FDA for safe use. Without formal safety evaluation, consumers are left exposed to unknown risks from products that have never undergone rigorous scientific review. The FDA has received adverse event reports associated with 7. Reports of harm linked to 7 include serious side effects such as liver toxicity, seizures, and respiratory issues, underscoring the need for immediate regulatory scrutiny. 7 has opioid-like effects and poses unique safety concerns. Because concentrated, synthetic 7 is a novel, potent opioid receptor agonist, its presence in unregulated consumer products raises red flags about addiction, misuse, and overdose. 'We urge the FDA and state regulators to continue down this path,' said Gallman. 'The longer these products are on the market, the greater the threat to public safety.' A Growing Chorus of Concern About Synthetic 7-Hydroxymitragynine Products The FDA warning letter also adds to a growing chorus of scientists, researchers, and industry stakeholders who have issued concerns about 7 products. In reaction to the FDA warning letter on social media, Dr. Christopher R. McCurdy, PhD, from the University of Florida College of Pharmacy said , 'The FDA is taking action on semi-synthetic kratom alkaloid derivatives, and this is exactly what we count on the FDA to do! These non-kratom products need to be removed from the market as they are no different from the many synthetic cannabinoids that made up 'spice' and caused harm to many … These novel chemicals synthesized from kratom extracts are potent opioids and a public health threat as currently marketed. They might be beneficial if pursued through the same pathways that all novel drugs gain approval.' In a statement released last week, Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP, a pharmacist, distinguished professor of pharmacy practice at the University of Connecticut School of Pharmacy, and Kratom Consumer Advisory Council chair said: 'Selling potent opioid receptor-stimulating 7 products in gas stations, convenience stores, and smoke shops in unlimited quantities within arm's reach of candy bars and energy drinks is a public health recipe for disaster. It allows a whole new generation of consumers to potentially get hooked on opioids, and we know where that leads.' In late 2024, leading kratom researchers at Johns Hopkins University and the University of Florida issued urgent warnings about proliferation of 7 products and for its potential for abuse, dependence, severe withdrawal , and even respiratory depression, dangers that run directly counter to it being marketed as a treatment for opioid addiction. GKC Committed to Transparency and Science The Global Kratom Coalition will continue to encourage and support federal and state regulators to investigate vendors who make false or misleading claims about their products, particularly those promoting unapproved drugs disguised as dietary supplements. About Global Kratom Coalition The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit Media Contact Patrick George +1 916-202-1982 [email protected] ### SOURCE: Global Kratom Coalition Copyright 2025 EZ Newswire
